NABIL INVESTMENT BANKING LIMITED...NABIL INVESTMENT BANKING LIMITED
How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January...
-
Upload
alexander-cook -
Category
Documents
-
view
221 -
download
1
Transcript of How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January...
![Page 1: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/1.jpg)
How to optimize the treatment of HCV-4 patients?
Nabil Antaki MD, FRCPC
Aleppo, Syria
Paris, January 30, 2012
![Page 2: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/2.jpg)
Case Presentation
• A 39-year-old Syrian male was diagnosed
6 months ago with genotype 4 HCV infection discovered during screening before blood donation.
He had no symptoms. BMI 27. No alcohol
His physical examination revealed no
abnormalities and his liver was not enlarged.
![Page 3: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/3.jpg)
The patient's initial laboratory results
• WBC: 5000 cells/mm3• Hemoglobin:15.4 g/dL • Platelet count: 168,000 cells/mm3• AST: 72 U/L ALT: 101 U/L• Total bilirubin: 0.4 mg/dL• Albumin: 4 g/L• HCV RNA: 900,000 IU/mL• Genotype 4c/d
![Page 4: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/4.jpg)
The patient's initial laboratory results
• Prothrombin time: 10.9 seconds; INR 1• TSH: 2.5 IU/mL (normal: 0.60-3.30 IU/mL)• Ferritin: 150 ng/mL (normal: 27-377 ng/mL)• Iron saturation: 30%• Alpha-fetoprotein: 2.5 ng/mL• liver biopsy :grade 2 and stage 2
(Metavir score)• IL28B: rs12979860 :CT
![Page 5: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/5.jpg)
• He was started on Peg-INF alfa-2a
180 µg/week plus RBV 1000 mg/day, and treatment was planned for 48 weeks.
![Page 6: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/6.jpg)
What are the pre-treatment predictors of response in this
patient?• Ethnicity?• Viral load?• Genotype sub-type?• Fibrosis?• IL28B?
![Page 7: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/7.jpg)
Fibrosis Stage and SVR Rates
65
46.646.4
21.236
27.3
0
100
F0 - F1 - F2 F3 - F4
Egyptian
French
African
• PEG-IFN-α-2b (1.5 μg / kg / week) plus RBV (1,000 – 1,200 mg / day) for 48 weeks
Roulot et al, J Viral Hepatol 2007
p=0.01
SVR (%)
Fibrosis score
![Page 8: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/8.jpg)
Baseline Viral Load and SVR Rates
67
2113
48
14
38
0
100
SVR Relapse Non-responder
HCV RNA at baseline<600,000, IU/ML (n=24)
HCV RNA at baseline>600,000, IU/ML (n=21)
Huepper et al, AASLD 2007
Patients (%)
_
![Page 9: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/9.jpg)
HCV-4 Subtypes & SVR Rates
54.9
40.332.4
0
100
Egypt France Africa
• Better SVR rates observed in patients with HCV-4a subtypes
Roulot et al, J Viral Hepat 2007n=242, p=<0.05
SVR (%)PEGIFN α-2b (1.5 mg / kg / week) plus RBV (1000 – 1200 mg / day) for 48 weeks
(4a) (4a,4d) (Multiple)
![Page 10: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/10.jpg)
Factors Associated with SVR in 108 HCV-4 Patients: Multiple Logistic Regression Analysis
Variable Odds Ratio 95% CI P value
Geographical Origin (Egyptian) 13.119 (3.089 – 55.706) <0.001
Insulin Sensitivity (HOMA-IR < 2) 5.314 (1.953 – 14.459) 0.001
Non-Severe Fibrosis (F0 - F2) 8.059 (2.512 – 25.855) <0.001
Factors associated with SVR
rates
0
20
40
60
80
Egyptians Caucasians Africans
%63
53
39
Moucari, J Hepatol 2009
![Page 11: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/11.jpg)
![Page 12: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/12.jpg)
C Allele is Associated with SVR (HCV-1)Percentage SVR by Genotype of rs12979860
0 20 40 60 80 100
C/C
T/C
T/T
SVR
CombinedEuropean AmericansAfrican AmericansHispanics
n = 70
n = 14
n = 102
n = 91n = 35
n = 433
n = 186
n = 559
n = 392
n = 30n = 26
n = 336 P = 1.37 x 10-28 vs T/T
Ge D, et al. Nature. 2009;461:399-401.
![Page 13: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/13.jpg)
IL28B in HCV-4Ethnicity CC (%) CT(%) TT(%) SVR(%)
Stättermayer1
n=10298% Egyptian 33.3 54 12.7 57
De Nicola2
n= 10368% Egyptian32% European
23 63 14 49
Asselah3
n= 8251%Egyptian34% European13%African
26.8 52.4 20.8 2
Antaki4
n= 194100% Caucasian 30.4 55.2 12 45
Worldwide distribution in Caucasian
38 50 12
1. Stättermayer et al,Clin Gastro and Hepatol, 2011. 2. De Nicola et al. Hepatology 2011.3 Assellah et al. J Hepatol 2011. 4. Antaki et al. submitted article
![Page 14: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/14.jpg)
SVR in HCV-4 stratified by IL28B genotype (rs12979860)
Stattermayer N=102
De Nicola N=103
Asselah N=82
Antaki N=194
0%10%20%30%40%50%60%70%80%90%
100%
CCCTTT
![Page 15: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/15.jpg)
SVR in HCV-4 stratified by IL28B genotype (rs8099917)
0%
10%
20%
30%
40%
50%
60%
70%
Stattermayer et al N=102 Antaki et al N=194
TT
TG/GG
![Page 16: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/16.jpg)
Week 4
• Following 4 weeks of HCV treatment, the patient presents with no anemia (Hb: 12.5 g/dL; HCT: 37.5%) and mild neutropenia (WBC: 2600 cells/mm3; ANC: 1600 cells/mm3). Neither condition requires dose reduction or addition of epoetin at this time.
• ALT and AST normal• The patient's HCV RNA is now undetectable.
![Page 17: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/17.jpg)
How would you manage his treatment at Week 4?
A. The patient is a responder and treatment should continue for 48 weeksB. The patient achieved RVR and 24 weeks of therapy is recommended C. The patient achieved RVR but his rs12979860 genotype is CT. He should continue therapy for 48 weeks
![Page 18: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/18.jpg)
Optimizing the response:
RESPONSE GUIDED THERAPY
The faster after initiating treatment, HCV RNA becomes undetectable, the higher is the SVR rate and shorter is the duration of treatment.
![Page 19: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/19.jpg)
Shorter treatment in HCV-4?Yes, If.....
![Page 20: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/20.jpg)
Impact of RVR
RVR, EVR as a guide for 24 w, 36 w or 48w
358 patients
Adaptive
N=308
Fixed
N=50
24 wRVR
N=6936 w
cEVR
N=79 48 wpEVR
N=160
48 w
Kamal et al, Hepatology. 2007
![Page 21: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/21.jpg)
EOT and SVR rates in HCV-G4 patients with RVR & EVR
9086
6570
86
76
56 58
0
25
50
75
100
Patients withRVR
Patients withcomplete EVR
Patients withpartial EVR
Fixed 48 weeks
EOT SVR
Kamal et al, Hepatology. 2007
% R
espo
nse
![Page 22: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/22.jpg)
RVR in HCV - 4
• 66 HCV-4 patients, Peg IFN α 2a and RBV
• RVR achieved in 45%• 26 RVR patients (86.7%) achieved an
SVR when treated for 24 weeks only• No relation: with baseline viral load
with dose of RBV
Ferenci P, et al. Gastroenterol. 2008
![Page 23: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/23.jpg)
SVR rates in HCV-G4 patients with RVR & EVR
Ferenci P, et al. Gastroenterol. 2008
0
20
40
60
80
100
≤ 400,000 400,000 -800,000
> 800,000
SV
R in
Pat
ien
ts A
chie
vin
g R
VR
(%
)
AllGenotype 1
F0-F2 F3-F4
By Baseline HCV RNA (IU/mL) By METAVIR Fibrosis Stage
Genotype 486.5 90.081.3 82.2 85.7
80.6
70.8
83.3
66.7
81.588.5
79.675.0 75.075.0
n/N = 61/74 52/64 9/10 37/45 25/31 12/14 17/24 12/18 5/6 97/119 74/93 23/26 18/24 3/415/20
![Page 24: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/24.jpg)
Impact of RVR and IL28B on SVR
• RVR achieved in 25.4 to 41% of patients.• In De Nicola study:
RVR 34% SVR 80% (CC100%, CT/TT 70%, p= 0.06)
No RVR 66% SVR 32% (CC 75%, CT/TT 23%, p= 0.001)
![Page 25: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/25.jpg)
Pre-treatment predictors of response
• Univariate analysis:1. Fibrosis (yes 1, 2, 4; no 3)
2. Ethnicity ( yes 2, no 3)
3. IL28B CC
4. Viral load
![Page 26: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/26.jpg)
On-treatment predictors of response
• Univariate analysis:1. Fibrosis (yes 1, 2, 4 no 3)
2. Ethnicity ( yes 2, no 3)
3. IL28B CC
4. Viral load
5. RVR
![Page 27: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/27.jpg)
predictors of response
• Multivariate analysis:1. Fibrosis
2. IL28B CC
3. RVR : the strongest predictor of SVR
![Page 28: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/28.jpg)
W 24
• At Week 24 of HCV therapy, the patient is tolerating treatment and remains fully compliant. The patient's liver enzymes are normal (AST: 23 IU/mL;
ALT: 19 IU/mL).• His current HCV RNA is undetectable
![Page 29: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/29.jpg)
What would you do?
• A. The patient should continue his current regimen through 48 weeks
• B. The patient should discontinue treatment and be monitored for the next 6 months to determine whether he has achieved SVR
![Page 30: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/30.jpg)
What would you do?
• The patient has no advanced fibrosis• His pre-treatment viral load was 900,000 IU
but this is not a poor predictive factor of response if he achieves RVR
• Although his IL28B genotype is CT, he achieved RVR (no statistical significance in SVR between CC and CT/TT in RVR patients)
• Treatment was stopped at W 24
![Page 31: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/31.jpg)
W 24 after ETR
• The patient returns 6 months after stopping treatment to determine whether he has achieved SVR.
• His liver enzymes remain within the normal range and HCV RNA remains negative, indicating that he has achieved SVR.
![Page 32: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/32.jpg)
The HCV- 4 algorithm: 2009
24 weeks
48 weeks
72Weeks ?
Week 4
Week 12
Week 24
-
-
-
+
- Or + >2log
-
+
+ <2log
-
Mild FibrosisLVL
![Page 33: How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649ddb5503460f94ad1e32/html5/thumbnails/33.jpg)
Week 4 _ + +
Week 12 _ (- )or > 2 log and CC
(+) or < 2 log CC or (-) but CT/TT
Week 24 _ _ _
Mild Fibrosis
24 weeks
48 weeks
72Weeks ???
The HCV- 4 proposed algorithm: 2012